Diabetes and alpha lipoic acid

Frontiers in Pharmacology

Volumn 2 NOV, Issue , 2011, Pages

  Golbidi, Saeid ^a   Badran, Mohammad ^a   Laher, Ismail ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alpha lipoic acid; Antioxidant; Diabetes; Nephropathy; Neuropathy; Oxidative stress

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ALPHA TOCOPHEROL; CYSTEINE; DEXLIPOTAM; DIHYDROLIPOATE; GLUTATHIONE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; METAL ION; METHIONINE; MITOGEN ACTIVATED PROTEIN KINASE; N(G),N(G) DIMETHYLARGININE; NITRIC ACID DERIVATIVE; NITRIC OXIDE SYNTHASE; NITRITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PROTEIN KINASE C; QUINAPRIL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOCTIC ACID; TRANSCRIPTION FACTOR NRF2; UBIDECARENONE; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

AGE; ANOREXIA; ANTIOXIDANT ACTIVITY; ARTICLE; CHELATION; CONCENTRATION RESPONSE; DIABETIC NEUROPATHY; DRUG ABSORPTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; KIDNEY FAILURE; LIPID PEROXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; RESPIRATORY CHAIN; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 84859479386     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2011.00069     Document Type: Article

References (194)

1. Abbasi, F., Asagmi, T., Cooke, J. P., Lamendola, C., McLaughlin, T., Reaven, G. M., Stuehlinger, M., and Tsao, P. S. (2001). Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am. J. Cardiol. 88, 1201-1203.
2. Achan, V., Broadhead, M., Malaki, M., Whitley, G., Leiper, J., MacAllister, R., and Vallance, P. (2003). Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler. Thromb. Vasc. Biol. 23, 1455-1459.
3. Aliciguzel, Y., Ozen, I., Aslan, M., and Karayalcin, U. (2003). Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J. Lab. Clin. Med. 142, 172-177.
4. Ambrosch, A., Dierkes, J., Lobmann, R., Kühne, W., König, W., Luley, C., and Lehnert, H. (2001). Relation between homocysteinaemia and diabetic neuropathy in patients with type 2 diabetes mellitus. Diabet. Med. 18, 185-192.
5. Ametov, A. S., Barinov, A., Dyck, P. J., Hermann, R., Kozlova, N., Litchy, W. J., Low, P. A., Nehrdich, D., Novosadova, M., O'Brien, P. C., Reljanovic, M., Samigullin, R., Schuette, K., Strokov, I., Tritschler, H. J., Wessel, K., Yakhno, N., Ziegler, D., and SYDNEY Trial Study Group. (2003). The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 26, 770-776.
6. Ametov, A. S., Novosadova, M. V., Barinov, A. N., Samigullin, R., and Trischler, H. J. (2010). Long-term effect of 3-week intravenous alphalipoic acid administration in symptomatic diabetic polyneutropathy with clinical manifestations. Ter. Arkh. 82, 61-64.
7. Anderson, K. A., Means, R. L., Huang, Q. H., Kemp, B. E., Goldstein, E. G., Selbert, M. A., Edelman, A. M., Fremeau, R. T., and Means, A. R. (1998). Components of a calmodulindependent protein kinase cascade. Molecular cloning, functional characterization and cellular localization of Ca2/calmodulin-dependent protein kinase beta. J. Biol. Chem. 273, 31880-31889.
8. Anderson, K. A., Ribar, T. J., Lin, F., Noeldner, P. K., Green, M. F., Muehlbauer, M. J., Witters, L. A., Kemp, B. E., and Means, A. R. (2008). Hypothalamic CaMKK2 contributes to the regulation of energy balance. Cell Metab. 7, 377-388.
9. Andersson, U., Filipsson, K., Abbott, C. R., Woods, A., Smith, K., Bloom, S. R., Carling, D., and Small, C. J. (2004). AMP-activated protein kinase plays a role in the control of food intake. J. Biol. Chem. 279, 12005-12008.
10. Androne, L., Gavan, N. A., Veresiu, I. A., and Orasan, R. (2000). In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In vivo 14, 327-330.
11. Ansar, H., Mazloom, Z., Kazemi, F., and Hejazi, N. (2011). Effect of alphalipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients. Saudi Med. J. 32, 584-588.
12. Artwohl, M., Muth, K., Kosulin, K., de Martin, R., Hölzenbein, T., Rainer, G., Freudenthaler, A., Huttary, N., Schmetterer, L., Waldhäusl, W. K., and BaumgartnerParzer, S. M. (2007). R-(+)-alphalipoic acid inhibits endothelial cell apoptosis and proliferation: involvement of Akt and retinoblastoma protein/E2F-1. Am. J. Physiol. Endocrinol. Metab. 293, E681-E69.
13. Baldwin, A. S. Jr. (1996). The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14, 649-683.
14. Barnes, P. J., and Karin, M. (1997). Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066-1071.
15. Bashan, N., Kovsan, J., Kachko, I., Ovadia, H., and Rudich, A. (2009). Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol. Rev. 89, 27-71.
16. Bast, A., and Haenen, G. R. (2003). Lipoic acid: a multifunctional antioxidant. Biofactors 17, 207-213.
17. Beckman, K. B., and Ames, B. N. (1998). The free radical theory of aging matures. Physiol. Rev. 78, 547-581.
18. Belfiore, A., Genua, M., and Malaguarnera, R. (2009). PPAR-gamma agonists and their effects on IGF-I receptor signaling: implications for cancer. PPAR Res. 2009, 830501.
19. Berger, J., and Moller, D. E. (2002). The mechanisms of action of PPARs. Annu.Rev.Med.53, 409-435.
20. Berkson, B. M. (1999). A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Med. Klin. (Munich); 94(Suppl. 3), 84-89.
21. Berlett, B. S., and Stadtman, E. R. (1997). Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem. 272, 20313-20316.
22. Biewenga, G. P., Haenen, G. R., and Bast, A. (1997). The pharmacology of the antioxidant lipoic acid. Gen. Pharmacol. 29, 315-331.
23. Bilska, A., and Wlodek, L. (2005). Lipoic acid the drug of the future? Pharmacol. Rep. 57, 570-577.
24. Böger, R. H., Bode-Böger, S. M., Szuba, A., Tsao, P. S., Chan, J. R., Tangphao, O., Blaschke, T. F., and Cooke, J. P. (1998). Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98, 1842-1847.
25. Böger, R. H., Bode-Böger, S. M., Thiele, W., Junker, W., Alexander, K., and Frölich, J. C. (1997). Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95, 2068-2074.
26. Bonomi, F., Cerioli, A., and Pagani, S. (1989). Molecular aspects of the removal of ferritin-bound iron by DL-dihydrolipoate. Biochim. Biophys. Acta 994, 180-186.
27. Boullier, A., Bird, D. A., Chang, M. K., Dennis, E. A., Friedman, P., GillotreTaylor, K., Hörkkö, S., Palinski, W., Quehenberger, O., Shaw, P., Steinberg, D., Terpstra, V., and Witztum, J. L. (2001). Scavenger receptors, oxidized LDL, and atherosclerosis. Ann. N. Y. Acad. Sci. 947, 214-222.
28. Brasier, A. R. (2006). The NF-kappaB regulatory network. Cardiovasc. Toxicol. 6, 111-130.
29. Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820.
30. Brownlee, M., Cerami, A., and Vlassara, H. (1988). Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab. Rev. 4, 437-451.
31. Burekovic, A., Terzic, M., Alajbegovic, S., Vukojevic, Z.,and Hadzic, N. (2008). The role of alpha-lipoic acid in diabetic polyneuropathy treatment. Bosn. J. Basic Med. Sci. 8, 341-345.
32. Busby, R. W., Schelvis, J. P. M., Yu, D. S., Babcock, G. T., and Marletta, M. A. (1999). Lipoic acid biosynthesis: LipA is an iron-sulphur protein. J. Am. Chem. Soc. 121, 4706-4707.
33. Busse, E., Zimmer, G., Schopohl, B., and Kornhuber, B. (1992). Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo. Arzneimittelforschung 42, 829-831.
34. Bustamante, J., Lodge, J. K., Marcocci, L., Tritschler, H. J., Packer, L., and Rihn, B. H. (1998). Alpha-lipoic acid in liver metabolism and disease. Free Radic. Biol. Med. 24, 1023-1039.
35. Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., and Butler, P. C. (2003). Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102110.
36. Butler, J. A., Hagen, T. M., and Moreau, R. (2009). Lipoic acid improves hypertriglyceridemia by stimulating triacylglycerol clearance and downregulating liver triacylglycerol secretion. Arch. Biochem. Biophys. 485, 63-71.
37. Cai, Y., Martens, G. A., Hinke, S. A., Heimberg, H., Pipeleers, D., and Van de Casteele, M. (2007). Increased oxygen radical formation and mitochondrial dysfunction mediate beta cell apoptosis under conditions of AMP-activated protein kinase stimulation. Free Radic. Biol. Med. 42, 64-78.
38. Calver, A., Collier, J., Leone, A., Moncada, S., and Vallance, P. (1993). Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J. Hum. Hypertens. 7, 193-194.
39. Cavaletti, G., Miloso, M., Nicolini, G., Scuteri, A., and Tredici, G. (2007). Emerging role of mitogen-activated protein kinases in peripheral neuropathies. J. Peripher. Nerv. Syst. 12, 175-194.
40. Ceriello, A., Mercuri, F., Quagliaro, L., Assaloni, R., Motz, E., Tonutti, L., and Taboga, C. (2001). Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 44, 834-838.
41. Chang, J. W., Lee, E. K., Kim, T. H., Min, W. K., Chun, S., Lee, K. U., Kim, S. B., and Park, J. S. (2007). Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study. Am.J.Nephrol.27, 70-74.
42. Chen, J., Jiang, W., Cai, J., Tao, W., Gao, X., and Jiang, X. (2005). Quantification of lipoic acid in plasma by high-performance liquid chromatography electrospray ionization mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 824, 249-257.
43. Cheung, P. C., Salt, I. P., Davies, S. P., Hardie, D. G., and Carling, D. (2000). Characterization of AMPactivated protein kinase gammasubunit isoforms and their role in AMP binding. Biochem. J. 346(Pt 3), 659-669.
44. Cox, A. G., Winterbourn, C. C., and Hampton, M. B. (2009). Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signaling. Biochem. J. 425, 313-325.
45. de Oliveira, A. M., Rondó, P. H., Luzia, L. A., D'Abronzo, F. H., and Illison, V. K. (2011). The effects of lipoic acid and α-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, double-blind, placebocontrolled trial. Diabetes Res. Clin. Pract. 92, 253-260.
46. Dickinson, D. A., and Forman, H. J. (2002a). Cellular glutathione and thiols metabolism. Biochem. Pharmacol. 64, 1021-1028.
47. Dickinson, D. A., and Forman, H. J. (2002b). Glutathione in defense and signaling: lessons from a small thiol. Ann. N. Y. Acad. Sci. 973, 488-504.
48. Dicter, N., Madar, Z., and Tirosh, O. (2002). Alpha-lipoic acid inhibits glycogen synthesis in rat soleus muscle via its oxidative activity and the uncoupling of mitochondria. J. Nutr. 132, 3001-3006.
49. Dovinova, I., Novotny, L., Rauko, P., and Kvasnicka, P. (1999). Combined effect of lipoic acid and doxorubicyn in murine leukemia. Neoplasma 46, 237-241.
50. Duckworth, W. C. (2001). Hyperglycemia and cardiovascular disease. Curr. Atheroscler. Rep. 3, 383-391.
51. El Midaoui, A., Wu, L., Wang, R., and de Champlain, J. (2006). Modulation of cardiac and aortic peroxisome proliferator-activated receptorgamma expression by oxidative stress in chronically glucose-fed rats. Am.J.Hypertens.19, 407-412.
52. Etoh, T., Inoguchi, T., Kakimoto, M., Sonoda, N., Kobayashi, K., Kuroda, J., Sumimoto, H., and Nawata, H. (2003). Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia 46, 1428-1437.
53. Evans, J. L., Goldfine, I. D., Maddux, B. A., and Grodsky, G. M. (2002). Oxidative stress and stressactivated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 23, 599-622.
54. Foretz, M., Ancellin, N., Andreelli, F., Saintillan, Y., Grondin, P., Kahn, A., Thorens, B., Vaulont, S., and Viollet, B. (2005). Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 54, 1331-1339.
55. Gardner, A. M., Lange-Carter, C. A., Vaillancourt, R. R., and Johnson, G. L. (1994). Measuring activation of kinases in mitogen-activated protein kinase regulatory network. Meth. Enzymol. 238, 258-270.
56. Gianturco, V., Bellomo, A., D'Ottavio, E., Formosa, V., Iori, A., Mancinella, M., Troisi, G., and Marigliano, V. (2009). Impact of therapy with alpha-lipoic acid (ALA) on the oxidative stress in the controlled NIDDM: a possible preventive way against the organ dysfunction? Arch. Gerontol. Geriatr. 49(Suppl.), 129-133.
57. Gilmore, T. D. (2006). Introduction to NF-kappa B: players, pathways, perspectives. Oncogene 25, 6680-6684.
58. Gleiter, C. H., Schug, B. S., Hermann, R., Elze, M., Blume, H. H., and Gundert Remy, U. (1996). Influence of food intake on the bioavailability of thioctic acid enantiomers. Eur. J. Clin. Pharmacol. 50, 513-514.
59. Golbidi, S., Ebadi, S. A., and Laher, I. (2011). Antioxidants in the treatment of diabetes. Curr. Diabetes Rev. 7, 106-125.
60. Golbidi, S., and Laher, I. (2010). Antioxidant therapy in human endocrine disorders. Med. Sci. Monit. 16, RA9- RA24.
61. Goodpaster, B. H., and Kelley, D. E. (2002). Skeletal muscle triglyceride: marker or mediator of obesityinduced insulin resistance in type 2 diabetes mellitus? Curr.Diab.Rep.2, 216-222.
62. Goralska, M., Dackor, R., Holley, B., and McGahan, M. C. (2003). Alpha lipoic acid changes iron uptake and storage in lens epithelial cells. Exp. Eye Res. 76, 241-248.
63. Green, K., Brand, M. D.,and Murphy, M. P. (2004). Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 53, S110-S118.
64. Griendling, K. K., and FitzGerald, G. A. (2003). Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108, 1912-1916.
65. Gu, X. M., Zhang, S. S., Wu, J. C., Tang, Z. Y., Lu, Z. Q., Li, H., Liu, C., Chen, L., and Ning, G. (2010). Efficacy and safety of high-dose α-lipoic acid in the treatment of diabetic polyneuropathy. Zhonghua Yi Xue Za Zhi 90, 2473-2476.
66. Guzik, T. J., Mussa, S., Gastaldi, D., Sadowski, J., Ratnatunga, C., Pillai, R., and Channon, K. M. (2002). Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105, 1656-1662.
67. Guzik, T. J., West, N. E., Black, E., McDonald, D., Ratnatunga, C., Pillai, R., and Channon, K. M. (2000). Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ. Res. 86, E85-E90.
68. Hagen, T. M., Vinarsky, V., Wehr, C. M., and Ames, B. N. (2000). (R)-alpha-lipoic acid reverses the age-associated increase in susceptibility of hepatocytes to tertbutylhydroperoxide both in vitro and in vivo. Antioxid. Redox Signal. 2, 473-483.
69. Hahm, J. R., Kim, B. J., and Kim, K. W. (2004). Clinical experience with thioctacid (thioctic acid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients. J. Diabetes Complicat. 18, 79-85.
70. Hall, K. E., Liu, J., Sima, A. A., and Wiley, J. W. (2001). Impaired inhibitory G-protein function contributes to increased calcium currents in rats with diabetic neuropathy. J. Neurophysiol. 86, 760-770.
71. Han, D., Handelman, G., Marcocci, L., Sen, C. K., Roy, S., Kobuchi, H., Tritschler, H. J., Flohé, L., and Packer, L. (1997). Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Biofactors 6, 321-338.
72. Haritoqlou, C., Gerss, J., Hammes, H. P., Kampik, A., Ulbig, M. W., and RETIPON Study Group. (2011). Alpha lipoic acid for the prevention of diabetic macular edema. Ophthalmologica 226, 127-137.
73. Harrison, E. H., and McCormick, D. B. (1974). The metabolism of dl(1,6-14C)lipoic acid in the rat. Arch. Biochem. Biophys. 160, 514-522.
74. Hawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., Frenguelli, B. G., and Hardie, D. G. (2005). Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMPactivated protein kinase. Cell Metab. 2, 9-19.
75. Heinisch, B. B., Francesconi, M., Mittermayer, F., Schaller, G., Gouya, G., Wolzt, M., and Pleiner, J. (2010). Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. Eur. J. Clin. Invest. 40, 148-154.
76. Heitzer, T., Finckh, B., Albers, S., Krohn, K., Kohlschütter, A., and Meinertz, T. (2001). Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic. Biol. Med. 31, 53-61.
77. Hermann, R., Hiebch, G., Borbe, H. O., Fieger-Buschgesf, H., Ruus, P., Nowak, H., Riethmuller-Winzen, H., Peukert, M., and Blume, H. (1996). Enantioselective pharmacokinetics and bioavailability of different racemic alpha lipoic acid formulations in healthy volunteers. Eur. J. Pharm. Sci. 4, 167-174.
78. Huang, E.A., and Gitelman, S. E. (2008). The effect of oral alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus. Pediatr. Diabetes 9, 69-73.
79. Hurley, R. L., Anderson, K. A., Franzone, J. M., Kemp, B. E., Means, A. R., and Witters, L. A. (2005). The Ca2/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem. 280, 29060-29066.
80. Ito, A., Tsao, P. S., Adimoolam, S., Kimoto, M., Ogawa, T., and Cooke, J. P. (1999). Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99, 3092-3095.
81. Jain, S. K., and Lim, G. (2000). Lipoic acid decreases lipid peroxidation and protein glycosylation and increases (Na(+) + K(+)) and Ca(++)ATPase activities in high glucose-treated human erythrocytes. Free Radic. Biol. Med. 29, 1122-1128.
82. Jensen, T. E., Rose, A. J., Jorgensen, S. B., Brandt, N., Schjerling, P., Wojtaszewski, J. F., and Richter, E. A. (2007). Possible CaMKK-dependent regulation of AMPK phosphorylation and glucose uptake at the onset of mild tetanic skeletal muscle contraction. Am. J. Physiol. Endocrinol. Metab. 292, E1308-E1317.
83. Jones, W., Li, X., Qu, Z. C., Perriott, L., Whitesell, R. R., and May, J. M. (2002). Uptake, recycling, and antioxidant actions of alpha-lipoic acid in endothelial cells. Free Radic. Biol. Med. 33, 83-93.
84. Kamenova, P. (2006). Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Hormones (Athens) 5, 251-258.
85. Kawabata, T., and Packer, L. (1994). Alpha-lipoate can protect against glycation of serum albumin, but not low density lipoprotein. Biochem. Biophys. Res. Commun. 203, 99-104.
86. Kim, M. S., Park, J. Y., Namkoong, C., Jang, P. G., Ryu, J. W., Song, H. S., Yun, J. Y., Namgoong, I. S., Ha, J., Park, I. S., Lee, I. K., Viollet, B., Youn, J. H., Lee, H. K., and Lee, K. U. (2004). Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMPactivated protein kinase. Nat. Med. 10, 727-733.
87. Kimoto, M., Tsuji, H., Ogawa, T., and Sasaoka, K. (1993). Detection of NG, NG-dimethylarginine dimethylaminohydrolase in the nitric oxide-generating systems of rats using monoclonal antibody. Arch. Biochem. Biophys. 300, 657-662.
88. Kishi, Y., Schmelzer, J. D., Yao, J. K., Zollman, P. J., Nickander, K. K., Tritschler, H. J., and Low, P. A. (1999). Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes 48, 2045-2051.
89. Kitada, M., Koya, D., Sugimoto, T., Isono, M., Araki, S., Kashiwagi, A., and Haneda, M. (2003). Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 52, 2603-2614.
90. Koh, E. H., Lee, W. J., Lee, S. A., Kim, E. H., Cho, E. H., Jeong, E., Kim, D. W., Kim, M. S., Park, J. Y., Park, K. G., Lee, H. J., Lee, I. K., Lim, S., Jang, H. C., Lee, K. H., and Lee, K. U. (2011). Effects of alpha-lipoic acid on body weight in obese subjects. Am.J.Med. 124, 851-858.
91. Kola, B., Boscaro, M., Rutter, G. A., Grossman, A. B., and Korbonits, M. (2006). Expanding role of AMPK in endocrinology. Trends Endocrinol. Metab. 17, 205-215.
92. Konrad, D., Somwar, R., Sweeney, G., Yaworsky, K., Hayashi, M., Ramlal, T., and Klip, A. (2001). The antihyperglycemic drug alpha-lipoic acid stimulates glucose uptake via both GLUT4 translocation and GLUT4 activation: potential role of p38 mitogen-activated protein kinase in GLUT4 activation. Diabetes 50, 1464-1471.
93. Krzyzanowska, K., Mittermayer, F., Krugluger, W., Schnack, C., Hofer, M., Wolzt, M., and Schernthaner, G. (2006). Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis 189, 236-240.
94. Krzyzanowska, K., Mittermayer, F., Schnack, C., Hofer, M., Wolzt, M., and Schernthaner, G. (2005). Circulating ADMA concentrations are elevated in hypopituitary adults with and without growth hormone deficiency. Eur. J. Clin. Invest. 35, 208-213.
95. Krzyzanowska, K., Mittermayer, F., Shnawa, N., Hofer, M., Schnabler, J., Etmüller, Y., Kapiotis, S., Wolzt, M., and Schernthaner, G. (2007). Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with type 2 diabetes and albuminuria. Diabet. Med. 24, 81-86.
96. Krzyzanowska, K., Mittermayer, F., Wolzt, M., and Schernthaner, G. (2008). ADMA, cardiovascular disease and diabetes. Diabetes Res. Clin. Pract. 82(Suppl.), s1226.
97. Kyriakis, J. M., and Avruch, J. (2001). Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81, 807-869.
98. Lee, B. W., Kwon, S. J., Chae, H. Y., Kang, J. G., Kim, C. S., Lee, S. J., Yoo, H. J., Kim, J. H., Park, K. S., and Ihm, S. H. (2009). Dose-related cytoprotective effect of alpha-lipoic acid on hydrogen peroxide-induced oxidative stress to pancreatic beta cells. Free Radic. Res. 43, 68-77.
99. Lee, C. K., Lee, E. Y., Kim, Y. G., Mun, S. H., Moon, H. B., and Yoo, B. (2008). Alpha-lipoic acid inhibits TNF-alpha induced NFkappa B activation through blocking of MEKK1-MKK4-IKK signaling cascades. Int. Immunopharmacol. 8, 362-370.
100. Lee, S., Park, Y., Zuidema, M. Y., Hannink, M., and Zhang, C. (2011). Effects of interventions on oxidative stress and inflammation of cardiovascular diseases. World J. Cardiol. 3, 18-24.
101. Lee, W. J., Kim, S. W., Kim, G. H., Han, S. M., Won, J. C., Jung, C. H., Park, H. S., Choi do, S., Lee, K. U., and Park, J. Y. (2010). Alpha-lipoic acid activates dimethylarginine dimethylaminohydrolase in cultured endothelial cells. Biochem. Biophys. Res. Commun. 398, 653-658.
102. Lee, W. J., Song, K. H., Koh, E. H., Won, J. C., Kim, H. S., Park, H. S., Kim, M. S., Kim, S. W., Lee, K. U., and Park, J. Y. (2005a). Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem. Biophys. Res. Commun. 332, 885-891.
103. Lee, W. J., Koh, E. H., Won, J. C., Kim, M. S., Park, J. Y., and Lee, K. U. (2005b). Obesity: the role of hypothalamic AMP-activated protein kinase in body weight regulation. Int. J. Biochem. Cell Biol. 37, 2254-2259.
104. Lin, K. Y., Ito, A., Asagami, T., Tsao, P. S., Adimoolam, S., Kimoto, M., Tsuji, H., Reaven, G. M., and Cooke, J. P. (2002). Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106, 987-992.
105. Liu, Y., and Gutterman, D. D. (2002). The coronary circulation in diabetes: influence of reactive oxygen species on K channel-mediated vasodilation. Vascul. Pharmacol. 38, 43-49.
106. Liu, Y., Terata, K., Chai, Q., Li, H., Kleinman, L. H., and Gutterman, D. D. (2002). Peroxynitrite inhibits Ca2+activated K+ channel activity in smooth muscle of human coronary arterioles. Circ. Res. 91, 1070-1076.
107. Lochhead, P. A., Salt, I. P., Walker, K. S., Hardie, D. G., and Sutherland, C. (2000). 5-aminoimidazole4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 49, 896-903.
108. Low, P. A., Nickander, K. K., and Tritschler, H. J. (1997). The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 46, s38-s42.
109. Marchetti, P., Del Guerra, S., Marselli, L., Lupi, R., Masini, M., Pollera, M., Bugliani, M., Boggi, U., Vistoli, F., Mosca, F., and Del Prato, S. (2004). Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J. Clin. Endocrinol. Metab. 89, 5535-5541.
110. Maritim, A. C., Sanders, R. A., and Watkins, J. B. III. (2003). Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17, 24-38.
111. Mary, J., Vougier, S., Picot, C. R., Perichon, M., Petropoulos, I., and Friguet, B. (2004). Enzymatic reactions involved in the repair of oxidized proteins. Exp. Gerontol. 39, 1117-1123.
112. McBride, A. E., and Silver, P. A. (2001). State of the arg: protein methylation at arginine comes of age. Cell 106, 5-8.
113. McCarty, M. F., Barroso-Aranda, J., and Contreras, F. (2009). The "rejuvenatory" impact of lipoic acid on mitochondrial function in aging rats may reflect induction and activation of PPAR-gamma coactivator-1alpha. Med. Hypotheses 72, 29-33.
114. McLellan, L. I., Lewis, A. D., Hall, D. J., Ansell, J. D., and Wolf, C. R. (1995). Uptake and distribution of N-acetylcysteine in mice: tissue-specific effects on glutathione concentrations. Carcinogenesis 16, 2099-2106.
115. Meffert, M. K., Chang, J. M., Wiltgen, B. J., Fanselow, M. S., and Baltimore, D. (2003). NF-kappa B functions in synaptic signaling and behavior. Nat. Neurosci. 6, 1072-1078.
116. Michael, L. F., Wu, Z., Cheatham, R. B., Puigserver, P., Adelmant, G., Lehman, J. J., Kelly, D. P.,and Spiegelman, B. M. (2001). Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc. Natl. Acad. Sci. U.S.A. 98, 3820-3825.
117. Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O'Rahilly, S., Palmer, C. N., Plutzky, J., Reddy, J. K., Spiegelman, B. M., Staels, B., and Wahli, W. (2006). International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 58, 726-741.
118. Midaoui, A. E., Elimadi, A., Wu, L., Haddad, P. S., and de Champlain, J. (2003). Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production. Am. J. Hypertens. 16, 173-179.
119. Minokoshi, Y., Alquier, T., Furukawa, N., Kim, Y. B., Lee, A., Xue, B., Mu, J., Foufelle, F., Ferré, P., Birnbaum, M. J., Stuck, B. J.,and Kahn, B. B. (2004). AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428, 569-574.
120. Mittermayer, F., Mayer, B. X., Meyer, A., Winzer, C., Pacini, G., Wagner, O. F., Wolzt, M., and Kautzky-Willer, A. (2002). Circulating concentrations of asymmetrical dimethyl-Larginine are increased in women with previous gestational diabetes. Diabetologia 45, 1372-1378.
121. Mittermayer, F., Pleiner, J., Francesconi, M., and Wolzt, M. (2010). Treatment with alpha-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus. Transl. Res. 155, 6-9.
122. Moini, H., Packer, L., and Saris, N. E. (2002). Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. Toxicol. Appl. Pharmacol. 182, 84-90.
123. Montagnani, M., Ravichandran, L. V., Chen, H., Esposito, D. L., and Quon, M. J. (2002). Insulin receptor substrate-1 and phosphoinositidedependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol. Endocrinol. 16, 1931-1942.
124. Morcos, M., Borcea, V., Isermann, B., Gehrke, S., Ehret, T., Henkels, M., Schiekofer, S., Hofmann, M., Amiral, J., Tritschler, H., Ziegler, R., Wahl, P., and Nawroth, P. P. (2001). Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res. Clin. Pract. 52, 175-183.
125. Mottley, C., and Mason, R. P. (2001). Sulfur-centered radical formation from the antioxidant dihydrolipoic acid. J. Biol. Chem. 276, 42677-42683.
126. Musi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., Moller, D. E., Thorell, A., and Goodyear, L. J. (2002). Metformin increases AMPactivated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51, 2074-2081.
127. Nagamatsu, M., Nickander, K. K., Schmelzer, J. D., Raya, A., Wittrock, D. A., Tritschler, H., and Low, P. A. (1995). Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18, 1160-1167.
128. Nickander, K. K., McPhee, B. R., Low, P. A., and Tritschler, H. (1996). Alphalipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radic. Biol. Med. 21, 631-639.
129. Niebch, G., Bu chele, B., Blome, J., Grieb, S., Brandt, G., Kampa, P., Raffel, H. H., Locher, M., Borbe, H. O., Nubert, I., and Fleischhauer, I. (1997). Enantioselective high-performance liquid chromatography assay of (+)Rand (-)S-alpha-lipoic acid in human plasma. Chirality 9, 32-36.
130. Nijveldt, R. J., Teerlink, T., Siroen, M. P., van Lambalgen, A. A., Rauwerda, J. A., and van Leeuwen, P. A. (2003a). The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin. Nutr. 22, 17-22.
131. Nijveldt, R. J., Teerlink, T., and van Leeuwen, P. A. (2003b). The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis. Clin. Nutr. 22, 99-104.
132. Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H. P., Giardino, I., and Brownlee, M. (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 404, 787-790.
133. Oberg, B. P., McMenamin, E., Lucas, F. L., McMonagle, E., Morrow, J., Ikizler, T. A., and Himmelfarb, J. (2004). Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 65, 1009-1016.
134. Ou, P., Tritschler, H. J., and Wolff, S. P. (1995). Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant? Biochem. Pharmacol. 50, 123-126.
135. Packer, L. (1998). alpha-Lipoic acid: a metabolic antioxidant which regulates NF-kappa B signal transduction and protects against oxidative injury. Drug Metab. Rev. 30, 245-275.
136. Packer, L., Witt, E. H., and Tritschler, H. J. (1995). Alpha-lipoic acid as a biological antioxidant. Free Radic. Biol. Med. 19, 227-250.
137. Palacka, P., Kucharska, J., Murin, J., Dostalova, K., Okkelova, A., Cizova, M., Waczulikova, I., Moricova, S., and Gvozdjakova, A. (2010). Complementary therapy in diabetic patients with chronic complications: a pilot study. Bratisl. Lek. Listy 111, 205-211.
138. Pershadsingh, H. A., Ho, C. I., Rajamani, J., Lee, C., Chittiboyina, A. G., Deshpande, R., Kurtz, T. W., Chan, J. Y., Avery, M. A., and Benson, S. C. (2005). Alpha lipoic acid is a weak dual PPAR α/γ agonist an ester derivative with increased PPAR α/γ efficacy and antioxidant activity. J. Appl. Res. 5, 510-523.
139. Petersen Shay, K., Moreau, R. F., Smith, E. J., and Hagen, T. M. (2008). Is alpha-lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity. IUBMB Life 60, 362-367.
140. Poh, Z. X., and Goh, K. P. (2009). A current update on the use of alpha lipoic acid in the management of type 2 diabetes mellitus. Endocr. Metab. Immune Disord. Drug Targets 9, 392-398.
141. Rahman, S. T., Merchant, N., Haque, T., Wahi, J., Bhaheetharan, S., Ferdinand, K. C., and Khan, B. V. (2011). The impact of lipoic acid on endothelial function and proteinuria in quinapril-treated diabetic patients with stage I hypertension: results from the quality study. J. Cardiovasc. Pharmacol. Ther. 12. [Epub ahead of print].
142. Reed, L. J. (1998). From lipoic acid to multi-enzyme complexes. Protein Sci. 7, 220-224.
143. Richards, S. K., Parton, L. E., Leclerc, I., Rutter, G. A., and Smith, R. M. (2005). Over-expression of AMP-activated protein kinase impairs pancreatic {beta}-cell function in vivo. J. Endocrinol. 187, 225-235.
144. Ruderman, N., and Flier, J. S. (2001). Cell biology. Chewing the fat - ACC and energy balance. Science 291, 2558-2559.
145. Saha, A. K., Avilucea, P. R., Ye, J. M., Assifi, M. M., Kraegen, E. W., and Ruderman, N. B. (2004). Pioglitazone treatment activates AMPactivated protein kinase in rat liver and adipose tissue in vivo. Biochem. Biophys. Res. Commun. 314, 580-585.
146. Saris, N. E., Karjalainen, A., Teplova, V. V., and Lindros, K. O. (1998). The stimulation of the mitochondrial permeability transition by dihydrolipoate and alpha-lipoate. Biochem. Mol. Biol. Int. 44, 127-134.
147. Schalkwijk, C. G., Lieuw-a-Fa, M., van Hinsbergh, V. W., and Stehouwer, C. D. (2002). Pathophysiological role of amadori-glycated proteins in diabetic microangiopathy. Semin. Vasc. Med. 2, 191-197.
148. Schepkin, V., Kawabata, T., and Packer, L. (1994). NMR study of lipoic acid binding to bovine serum albumin. Biochem. Mol. Biol. Int. 33, 879-886.
149. Schmidt, A. M., Hori, O., Brett, J., Yan, S. D., Wautier, J. L., and Stern, D. (1994). Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler. Thromb. 14, 1521-1528.
150. Sena, C. M., Nunes, E., Louro, T., Proença, T., Fernandes, R., Boarder, M. R., and Seiça, R. M. (2008). Effects of alpha-lipoic acid on endothelial function in aged diabetic and high-fat fed rats. Br. J. Pharmacol. 153, 894-906.
151. Shackelford, D. B., and Shaw, R. J. (2009). The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 9, 563-575.
152. Shay, K. P., Moreau, R. F., Smith, E. J., Smith, A. R., and Hagen, T. M. (2009). Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim. Biophys. Acta 1790, 1149-1160.
153. Shen, Q. W., Zhu, M. J., Tong, J., Ren, J., and Du, M. (2007). Ca2+/calmodulin-dependent protein kinase kinase is involved in AMP-activated protein kinase activation by alpha-lipoic acid in C2C12 myotubes. Am. J. Physiol. Cell Physiol. 293, C1395-C1403.
154. Singh, U., and Jialal, I. (2008). Alphalipoic acid supplementation and diabetes. Nutr. Rev. 66, 646-657.
155. Smith, A. R., and Hagen, T. M. (2003). Vascular endothelial dysfunction in aging: loss of Aktdependent endothelial nitric oxide synthase phosphorylation and partial restoration by (R)-alpha-lipoic acid. Biochem. Soc. Trans. 31, 1447-1449.
156. Smith, A. R., Shenvi, S. V., Widlansky, M., Suh, J. H., and Hagen, T. M. (2004). Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr. Med. Chem. 11, 1135-1146.
157. Soriano, F. G., Virag, L., and Szabo, C. (2001). Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J. Mol. Med. 79, 437-448.
158. Stahmann, N., Woods, A., Carling, D., and Heller, R. (2006). Thrombin activates AMP-activated protein kinase in endothelial cells via a pathway involving Ca2+/calmodulindependent protein kinase kinase beta. Mol. Cell Biol. 26, 5933-5945.
159. Stevens, M. J., Obrosova, I., Cao, X., Van Huysen, C., and Greene, D. A. (2000). Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 49, 1006-1015.
160. Strokov, I. A., Manukhina, E. B., Bakhtina, L. Y., Malyshev, I. Y., Zoloev, G. K., Kazikhanova, S. I., and Ametov, A. S. (2000). The function of endogenous protective systems in patients with insulin-dependent diabetes mellitus and polyneuropathy: effect of antioxidant therapy. Bull. Exp. Biol. Med. 130, 986-990.
161. Stühlinger, M. C., Abbasi, F., Chu, J. W., Lamendola, C., McLaughlin, T. L., Cooke, J. P., Reaven, G. M., and Tsao, P. S. (2002). Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287, 1420-1426.
162. Suh, J. H., Moreau, R., Heath, S. H., and Hagen, T. M. (2005). Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep. 10, 52-60.
163. Suh, J. H., Wang, H., Liu, R. M., Liu, J., and Hagen, T. M. (2004). (R)alpha-lipoic acid reverses the agerelated loss in GSH redox status in post-mitotic tissues: evidence for increased cysteine requirement for GSH synthesis. Arch. Biochem. Biophys. 423, 126-135.
164. Surdacki, A., Nowicki, M., Sandmann, J., Tsikas, D., Boeger, R. H., Bode-Boeger, S. M., Kruszelnicka Kwiatkowska, O., Kokot, F., Dubiel, J. S., and Froelich, J. C. (1999). Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J. Cardiovasc. Pharmacol. 33, 652-658.
165. Suzuki, Y. J., Tsuchiya, M., and Packer, L. (1992). Lipoate prevents glucoseinduced protein modifications. Free Radic. Res. Commun. 17, 211-217.
166. Tamás, P., Hawley, S. A., Clarke, R. G., Mustard, K. J., Green, K., Hardie, D. G., and Cantrell, D. A. (2009). The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 9, 563-575.
167. Taniyama, Y., and Griendling, K. K. (2003). Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42, 1075-1081.
168. Tankova, T., Koev, D., and Dakovska, L. (2004). Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study). Rom. J. Intern. Med. 42, 457-464.
169. Targonsky, E. D., Dai, F., Koshkin, V., Karaman, G. T., Gyulkhandanyan, A. V., Zhang, Y., Chan, C. B., and Wheeler, M. B. (2006). Alpha-lipoic acid regulates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Diabetologia 49, 1587-1598.
170. Tarnow, L., Hovind, P., Teerlink, T., Stehouwer, C. D., and Parving, H. H. (2004). Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 27, 765-769.
171. Teichert, J., Tuemmers, T., Achenbach, H., Preiss, C., Hermann, R., Ruus, P., and Preiss, R. (2005). Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease. J. Clin. Pharmacol. 45, 313-328.
172. Tian, B., and Brasier, A. R. (2003). Identification of a nuclear factor kappa B-dependent gene network. Recent Prog. Horm. Res. 58, 95-130.
173. Turko, I. V., Marcondes, S., and Murad, F. (2001). Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA: 3-oxoacid CoAtransferase. Am. J. Physiol. Heart Circ. Physiol. 281, H2289-H2294.
174. Vallianou, N., Evangelopoulos, A., and Koutalas, P. (2009). Alpha-lipoic acid and diabetic neuropathy. Rev. Diabet. Stud. 6, 230-236.
175. Vega-Lopez, S., Devaraj, S., and Jialal, I. (2004). Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J. Investig. Med. 52, 24-32.
176. Viana, A. Y., Sakoda, H., Anai, M., Fujishiro, M., Ono, H., Kushiyama, A., Fukushima, Y., Sato, Y., Oshida, Y., Uchijima, Y., Kurihara, H., and Asano, T. (2006). Role of hepatic AMPK activation in glucose metabolism and dexamethasoneinduced regulation of AMPK expression. Diabetes Res. Clin. Pract. 73, 135-142.
177. Viollet, B., Lantier, L., Devin-Leclerc, J., Hebrard, S., Amouyal, C., Mounier, R., Foretz, M., and Andreelli, F. (2009). Targeting the AMPK pathway for the treatment of type 2 diabetes. Front. Biosci. 14, 3380-3400.
178. Vossler, S., Füllert, S., Schneider, F., Haak, E., Haak, T., Samigullin, R., Tritschler, H., Tooke, J. E., and Konrad, T. (2007). Pharmacodynamic effects of orally administered dexlipotam on endothelial function in type 2-diabetic patients. Int. J. Clin. Pharmacol. Ther. 45, 385-393.
179. Wada, H., Shintani, D., and Ohlrogge, J. (1997). Why do mitochondria synthesize fatty acids? Evidence for involvement in lipoic acid production. Proc. Natl. Acad. Sci. U.S.A. 94, 1591-1596.
180. Wang, Y., Li, X., Guo, Y., Chan, L., and Guan, X. (2010). Alpha-lipoic acid increases energy expenditure by enhancing adenosine monophosphate-activated protein kinase-peroxisome proliferatoractivated receptor-gamma coactivator-1alpha signaling in the skeletal muscle of aged mice. Metabolism 59, 967-976.
181. Widmann, C., Gibson, S., Jarpe, M. B., and Johnson, G. L. (1999). Mitogenactivated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. 79, 143-180.
182. Winder, W. W. (2001). Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. J. Appl. Physiol. 91, 1017-1028.
183. Winder, W. W., and Hardie, D. G. (1996). Inactivation of acetyl-CoA carboxylase and activation of AMPactivated protein kinase in muscle during exercise. Am. J. Physiol. 270, E299-E304.
184. Xi, X., Han, J., and Zhang, J. Z. (2001). Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase. J. Biol. Chem. 276, 41029-41034.
185. Xiang, G. D., Sun, H. L., Zhao, L. S., Hou, J., Yue, L., and Xu, L. (2008). The antioxidant alpha-lipoic acid improves endothelial dysfunction induced by acute hyperglycemia during OGTT in impaired glucose tolerance. Clin. Endocrinol. (Oxf.) 68, 716-723.
186. Ying, Z., Kampfrath, T., Sun, Q., Parthasarathy, S., and Rajagopalan, S. (2011). Evidence that α-lipoic acid inhibits NFκ-B activation independent of its antioxidant function. Inflamm. Res. 60, 219-225.
187. Zeigler, M. E., Chi, Y., Schmidt, T., and Varani, J. (1999). Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J. Cell. Physiol. 180, 271-284.
188. Zhang, W. J., and Frei, B. (2001). Alphalipoic acid inhibits TNF-alphainduced NF-kappa B activation and adhesion molecule expression in human aortic endothelial cells. FASEB J. 15, 2423-2432.
189. Zhang, W. J., Wei, H., Hagen, T., and Frei, B. (2007). Alpha-lipoic acid attenuates LPS-induced inflammatory responses by activating the phosphoinositide 3-kinase/Akt signaling pathway. Proc. Natl. Acad. Sci. U.S.A. 104, 4077-4082.
190. Zhang, Y., Han, P., Wu, N., He, B., Lu, Y., Li, S., Liu, Y., Zhao, S., Liu, L., and Li, Y. (2011). Amelioration of lipid abnormalities by α-lipoic acid through antioxidative and antiinflammatory effects. Obesity (Silver Spring) 19, 1647-1653.
191. Ziegler, D. (2006). Treatment of diabetic polyneuropathy: update 2006. Ann. N. Y. Acad. Sci. 1084, 250-266.
192. Ziegler, D., Ametov, A., Barinov, A., Dyck, P. J., Gurieva, I., Low, P. A., Munzel, U., Yakhno, N., Raz, I., Novosadova, M., Maus, J., and Samigullin, R. (2006). Oral treatment with alpha lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 29, 2365-2370.
193. Ziegler, D., Low, P. A., Litchy, W. J., Boulton, A. J., Vinik, A. I., Freeman, R., Samigullin, R., Tritschler, H., Munzel, U., Maus, J., Schütte, K., and Dyck, P. J. (2011). Efficacy and safety of antioxidant treatment with {alpha}-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 34, 2054-2060.
194. Zoccali, C., Bode-Böger, S., Mallamaci, F., Benedetto, F., Tripepi, G., Malatino, L., Cataliotti, A., Bellanuova, I., Fermo, I., Frölich, J., and Böger, R. (2001). Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358, 2113-2117.